{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:52:56Z","timestamp":1782395576175,"version":"3.54.5"},"reference-count":18,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Ado-trastuzumab emtansine (T-DM1) is a targeted agent for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which combines the anti-tumor activity of trastuzumab with the cytotoxic effect of DM1, a microtubule inhibitor. Although T-DM1 has improved outcomes in patients with HER2-positive breast cancer, portal hypertension may occur during treatment in the absence of overt cirrhosis on liver biopsy. These clinical and pathological features are consistent with porto-sinusoidal vascular disorder (PSVD). This study aimed to summarize the reported clinical, biochemical, imaging, histological, therapeutic, and prognostic features of T-DM1-associated PSVD. Methods: PubMed and Web of Science were searched for published cases of T-DM1-associated PSVD. Given the evolving terminology of PSVD, related terms, including non-cirrhotic portal hypertension and nodular regenerative hyperplasia, were also included in the search strategy. If the patient has a recorded history of T-DM1 exposure and the liver biopsy results meet PSVD criteria, the case is included regardless of whether there is clinical, endoscopic, or imaging evidence of portal hypertension. Cases without liver biopsy or with features suggestive of overt cirrhosis were excluded. Patient-level data were extracted and descriptively summarized, including demographic characteristics, clinical manifestations, biochemical indicators, imaging examination results, liver biopsy results, treatment methods, and prognosis. Unreported data were considered missing values and were not imputed. Results: Seven eligible articles comprising eight patients were identified. All patients were female, with a mean age of 60.38 years and a median age of 62.50 years. The interval from T-DM1 initiation to PSVD diagnosis ranged from 6 to 30 months. When reported, the mean interval from treatment initiation to symptom onset was 18.3 months. Thrombocytopenia and splenomegaly were observed in 7 of 8 patients. Mild elevations in alanine aminotransferase and aspartate aminotransferase were observed in all patients. Liver biopsy showed thinned and disorganized hepatic plates accompanied by nodular regeneration of hepatocytes in six patients. Clinical improvement was observed after discontinuation or modification of T-DM1 in most cases. Conclusions: T-DM1-associated PSVD is a rare but clinically significant complication that may develop months after treatment initiation. It commonly presents with thrombocytopenia, splenomegaly, gastrointestinal bleeding, or mild liver biochemical abnormalities in the absence of overt cirrhosis. Early recognition of unexplained platelet decline, splenic enlargement, or portal hypertension-related findings during T-DM1 therapy may facilitate timely diagnosis and individualized management. Withdrawal or modification of the suspected drug may contribute to clinical improvement, although further studies are needed to clarify the mechanism and optimal management strategy.<\/jats:p>","DOI":"10.3390\/jcm15134950","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:37:55Z","timestamp":1782391075000},"page":"4950","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab Emtansine\u2013Associated Porto-Sinusoidal Vascular Disorder: Clinical Features and Outcomes from Published Cases"],"prefix":"10.3390","volume":"15","author":[{"given":"Jiazheng","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-9901","authenticated-orcid":false,"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1002\/hep.26904","article-title":"Idiopathic Portal Hypertension: Natural History and Long-Term Outcome","volume":"59","author":"Siramolpiwat","year":"2014","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-Sinusoidal Vascular Disease: Proposal and Description of a Novel Entity","volume":"4","author":"Rautou","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jhep.2022.05.033","article-title":"Porto-Sinusoidal Vascular Disorder","volume":"77","author":"Sempoux","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1200\/JCO.2009.22.1507","article-title":"Understanding the Mechanisms behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer","volume":"27","author":"Spector","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/138920012802138598","article-title":"Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): An Emphasis on Preclinical and Clinical Catabolism","volume":"13","author":"Shen","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"ref_7","first-page":"e85981","article-title":"Porto-Sinusoidal Vascular Liver Disease Associated with Trastuzumab Emtansine: A Case Report","volume":"17","author":"Antunes","year":"2025","journal-title":"Cureus"},{"key":"ref_8","first-page":"e86333","article-title":"Trastuzumab Emtansine (T-DM1)-Induced Porto-Sinusoidal Vascular Disorder: A Case Report","volume":"17","author":"Fernandes","year":"2025","journal-title":"Cureus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1200\/JCO.2013.49.8543","article-title":"Nodular Regenerative Hyperplasia After Treatment with Trastuzumab Emtansine","volume":"34","author":"Force","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1159\/000521933","article-title":"Trastuzumab Emtansine-Induced Nodular Regenerative Hyperplasia: Is Dose Reduction Enough as a Preventable Measure?","volume":"40","author":"Garrido","year":"2022","journal-title":"Dig. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1177\/1078155220910252","article-title":"Safety of Trastuzumab after Trastuzumab Emtansine-Induced Nodular Regenerative Hyperplasia: A Case Report","volume":"26","author":"Hassan","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_12","first-page":"26","article-title":"Trastuzumab Emtansine Associated Nodular Regenerative Hyperplasia: A Case Report and Review of Literature","volume":"5","author":"Prochaska","year":"2016","journal-title":"Cancer Treat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.5604\/01.3001.0012.7207","article-title":"Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?","volume":"17","author":"Lepelley","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12072-007-9010-9","article-title":"Noncirrhotic Portal Fibrosis\/Idiopathic Portal Hypertension: APASL Recommendations for Diagnosis and Treatment","volume":"1","author":"Sarin","year":"2007","journal-title":"Hepatol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Nadal-Serrano, M., Morancho, B., Escriv\u00e1-de-Roman\u00ed, S., Bernad\u00f3 Morales, C., Luque, A., Escorihuela, M., Espinosa Bravo, M., Peg, V., Dijcks, F.A., and Dokter, W.H.A. (2020). The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers, 12.","DOI":"10.3390\/cancers12030670"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) Retains All the Mechanisms of Action of Trastuzumab and Efficiently Inhibits Growth of Lapatinib Insensitive Breast Cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0034-1375963","article-title":"Drug-Induced Nodular Regenerative Hyperplasia","volume":"34","author":"Ghabril","year":"2014","journal-title":"Semin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/1535-7163.MCT-15-0580","article-title":"Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity","volume":"15","author":"Yan","year":"2016","journal-title":"Mol. Cancer Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4950\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:35:47Z","timestamp":1782394547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/4950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":18,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15134950"],"URL":"https:\/\/doi.org\/10.3390\/jcm15134950","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}